SPARC intimates of achievement of milestone - commercialisation of XELPROS
SPARC had out-licensed XELPROS to Sun Pharma in June 2015 and this commercialisation of XELPROS, has triggered a milestone payment of USD 10 Million and sales linked royalties, by Sun Pharma to SPARC.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content